Paul Andrew Antony
Overview
Explore the profile of Paul Andrew Antony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4 T Cell Adoptive Immunotherapy
Goding S, Wilson K, Rosinsky C, Antony P
J Immunol
. 2018 Apr;
200(9):3304-3311.
PMID: 29602773
Immunotherapy is becoming the standard of care for melanoma. However, resistance to therapy is a major problem. Previously, we showed that tumor-specific, cytotoxic CD4 T cells from tyrosinase-related protein 1...
2.
Rosinsky C, Antony P
J Immunother Cancer
. 2016 Mar;
4:16.
PMID: 26981246
The innate and adaptive immune systems have evolved together to fight infection and cancerous tissues. The innate immune system emerges first with the adaptive immune system following, both ostensibly being...
3.
Wilson K, Goding S, Neely H, Harris K, Antony P
Oncoimmunology
. 2015 Sep;
4(8):e1019196.
PMID: 26405570
Five-year survival rates for patients diagnosed with metastatic melanoma are less than 5%. Adoptive cell transfer (ACT) has achieved an objective response of 50% by Response Evaluation Criteria in Solid...
4.
Goding S, Wilson K, Xie Y, Harris K, Baxi A, Akpinarli A, et al.
J Immunol
. 2013 Mar;
190(9):4899-909.
PMID: 23536636
Recurrent solid malignancies are often refractory to standard therapies. Although adoptive T cell transfer may benefit select individuals, the majority of patients succumb to their disease. To address this important...
5.
Xie Y, Akpinarli A, Maris C, Hipkiss E, Lane M, Kwon E, et al.
J Exp Med
. 2010 Feb;
207(3):651-67.
PMID: 20156973
In vitro differentiated CD8(+) T cells have been the primary focus of immunotherapy of cancer with little focus on CD4(+) T cells. Immunotherapy involving in vitro differentiated T cells given...
6.
Antony P, Restifo N
J Immunother
. 2005 Feb;
28(2):120-8.
PMID: 15725955
CD4+CD25+ T regulatory (Treg) cells control immunologic tolerance to self-antigens and play a role in suppressing antitumor immune responses, but the mechanism of suppression in vivo remains uncertain. Recently, signaling...
7.
Antony P, Restifo N
J Immunother
. 2002 May;
25(3):202-6.
PMID: 12000861
After years of banishment from mainstream immunology, the notion that one subset of T cells can exert regulatory effects on other T lymphocytes is back in fashion. Recent work in...